D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure - Trial NCT06300177
Access comprehensive clinical trial information for NCT06300177 through Pure Global AI's free database. This Phase 3 trial is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and is currently Recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 522 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Timeline & Enrollment
Phase 3
Mar 28, 2024
Dec 01, 2027
Primary Outcome
Progression-free survival (PFS)
Summary
The purpose of this project is to evaluate progression-free survival (PFS) of D-1553 Tablet
 versus Docetaxel Injection in subjects with prior standard therapy failure kirsten rat
 sarcoma viral oncogene (KRAS) G12C mutation positive locally advanced or metastatic non small
 cell lung cancer (NSCLC), progression-free survival (PFS) as assessed by the Independent
 Review Committee (IRC) based on RECIST 1.1 was used as the primary endpoint.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06300177
Non-Device Trial